Company intelligence / Profile preview

Neurolixis

Park Ridge, New Jersey, USAneurolixis.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Neurolixis has demonstrated clinical proof-of-concept for NLX‑112 in dyskinesia associated with Parkinson’s disease in a completed Phase 2A trial as of March 2023. NLX‑101 has advanced to Phase 1 for rare autism spectrum disorders including Rett syndrome and Fragile X syndrome. NLX‑204 remains at the preclinical stage targeting depression and pain. The company emphasizes high selectivity and innovative mechanisms of action at serotonin receptors.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (novel chemical entities)
Industry: Biotech

Drug pipeline

4 assets

NLX-112

3 more assets in the full pipeline.

Request access →

Partnerships

Receives research grants from organizations such as Parkinson's UK, Michael J. Fox Foundation for Parkinson's Research, US Department of Defense, Rett Syndrome Research Trust, International Rett Syndrome Foundation

Beyond the preview

Go deeper on Neurolixis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurolixis.

Explore the full profile